Biotech financings and M&A
activeReport on major biotech private financings / IPOs and M&A.
3 candidate storiesdeep depthlast week
Reporters
2
2 active
Target runtime
18m
Editor-configured
Generation mode
Live
Live APIs configured
Editor Snapshot
Episode direction
Conversational, precise, and audio-first. Make the briefing feel like a thoughtful private intelligence memo spoken aloud. The audience is an oncology-focused biotech venture capitalist with technical depth. Commentary should assume an app…
Allocations: Spend roughly equal time across active reporters unless one topic has materially stronger stories.
Priorities: Prioritize genuinely new developments, primary sources when possible, and clear explanations of why each story matters (but with the context of the target audience - don't make ov…
Reporters
New ReporterPreclinical research
activeCovers early-stage research published by PIs at academic institutions, biotech, pharma.
3 candidate storiesdeep depthlast month
Recent Episodes
All EpisodesLatest Developments in Oncology and Biotech Financing
Created May 17, 2026, 3:31 AM
Completed May 17, 2026, 4:22 AM
Latest Trends in Oncology Biotech Funding and Research
Created May 14, 2026, 3:07 PM
Completed May 14, 2026, 4:46 PM
Insights on Emerging Trends in Oncology and Biotech Finance
Created May 14, 2026, 1:03 AM
Completed May 14, 2026, 4:18 AM
Coverage memory
Recently approved topics
This running log is fed back into future generations so the editor can avoid stale repetition and each reporter can remember which approved subtopics they have already covered.
Biotech financings and M&A
mediumrepeat after 1 monthReporter: Biotech financings and M&A
Last covered May 17, 2026, 3:31 AM
The $15.2 billion partnership represents significant trends in global pharmaceutical collaborations and innovation access, drawing investor attention.
Preclinical research
narrowrepeat after 2 monthsReporter: Preclinical research
Last covered May 17, 2026, 3:31 AM
Focuses on specific findings related to daraxonrasib, vital insights warrant careful tracking without unnecessary repetition soon.
Preclinical research
narrowrepeat after 2 monthsReporter: Biotech financings and M&A
Last covered May 17, 2026, 3:31 AM
Discusses the promising combination of INBRX-106 with Keytruda, highlighting evolving treatment landscapes that need monitoring without frequent repeats.